<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2300/8959438/94c948b85221/fonc-12-789228-g002.jpg"/> </div> <div class="text-side"> <h1>Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor.</h1> <p>PD-L1 immunohistochemistry staining as a ratio of tumor cell membrane, VENTANA PD-L1 (SP263) Assay, Roche. (A) Positive control, 200×. (B) Negative control, 200×. (C) Immunohistochemistry of tumor tissue, 400×. (D) H&amp;E staining of tumor tissue, 400×. Testing standard: only the staining ratio of the tumor cell membrane was calculated. The proportion of immunocyte staining was not calculated. The staining ratio of PD-L1 was divided into five levels, as follows: &lt;1%, ≥1%, ≥5%, ≥10%, and ≥50%. PD-L1, programmed death-ligand 1.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35356229/" target="_blank">35356229</a></p><p>Type: Premalignant/Malignant, Category: Keratinocytic</p>
</div> </div></div></body></html>